Daniel Elson

Mr. Daniel Elson

Oregon State University - Department of Environmental and Molecular Toxicology
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Biology
Verified
Journal Article
Open access
PDF file
JGJohn T. Gamble
John T. Gamble
Daniel ElsonDaniel Elson
Daniel Elson
JGJuliet A. Greenwood
Juliet A. Greenwood
Robyn Leigh TanguayRobyn Leigh Tanguay
Robyn Leigh Tanguay
SKSiva Kolluri
Siva Kolluri
In order to develop new cancer therapeutics, rapid, reliable, and relevant biological models are required to screen and validate drug candidates for both efficacy and safety. In recent years, the zebrafish (Danio rerio) has emerged as an excellent model organism suited for these goals. Larval fish or immunocompromised adult fish are used to engraft human cancer cells and serve as a platform for screening potential drug candidates. With zebrafish sharing ~80% of disease-related orthologous genes with humans, they provide a low cost, high-throughput alternative to mouse xenografts that is relevant to human biology. In this review, we provide background on the methods and utility of zebrafish xenograft models in cancer research.

30 March 2023 in Biology
Verified
Journal Article
Open access
PDF file
Daniel ElsonDaniel Elson
Daniel Elson
SKSiva Kolluri
Siva Kolluri
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor involved in regulating a wide range of biological responses. A diverse array of xenobiotics and endogenous small molecules bind to the receptor and drive unique phenotypic responses. Due in part to its role in mediating toxic responses to environmental pollutants, AhR activation has not been traditionally viewed as a viable therapeutic approach. Nonetheless, the expression and activation of AhR can inhibit the proliferation, migration, and survival of cancer cells, and many clinically approved drugs transcriptionally activate AhR. Identification of novel select modulators of AhR-regulated transcription that promote tumor suppression is an active area of investigation. The development of AhR-targeted anticancer agents requires a thorough understanding of the molecular mechanisms driving tumor suppression. Here, we summarized the tumor-suppressive mechanisms regulated by AhR with an emphasis on the endogenous functions of the receptor in opposing carcinogenesis. In multiple different cancer models, the deletion of AhR promotes increased tumorigenesis, but a precise understanding of the molecular cues and the genetic targets of AhR involved in this process is lacking. The intent of this review was to synthesize the evidence supporting AhR-dependent tumor suppression and distill insights for development of AhR-targeted cancer therapeutics.

22 July 2022 in FEBS Letters
Verified
Journal Article
Closed access
Daniel ElsonDaniel Elson
Daniel Elson
BNBach D. Nguyen
Bach D. Nguyen
RWRhand Wood
Rhand Wood
YZYi Zhang
Yi Zhang
VPVeronica Puig‐Sanvicens
Veronica Puig‐Sanvicens
SKSiva Kolluri
Siva Kolluri

16 March 2019 in Apoptosis
Verified
Journal Article
Closed access
PDF file
EMErin Morgan
Erin Morgan
JGJohn T. Gamble
John T. Gamble
MPMartin C. Pearce
Martin C. Pearce
Daniel ElsonDaniel Elson
Daniel Elson
RTRobert L. Tanguay
Robert L. Tanguay
NRNorbert O. Reich
Norbert O. Reich

2 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MDMichael I. Dorrell
Michael I. Dorrell
HKHeidi R. Kast-Woelbern
Heidi R. Kast-Woelbern
RBRyan T. Botts
Ryan T. Botts
SBStephen A. Bravo
Stephen A. Bravo
JTJacob R. Tremblay
Jacob R. Tremblay
JSJeffrey M Snowbarger
Jeffrey M Snowbarger
Tumor angiogenesis is critical for the growth and progression of cancer. As such, angiostasis is a treatment modality for cancer with potential utility for multiple types of cancer and fewer side effects. However, clinical success of angiostatic monotherapies has been moderate, at best, causing angiostatic treatments to lose their early luster. Previous studies demonstrated compensatory mechanisms that drive tumor vascularization despite the use of angiostatic monotherapies, as well as the potential for combination angiostatic therapies to overcome these compensatory mechanisms. We screened clinically approved angiostatics to identify specific combinations that confer potent inhibition of tumor-induced angiogenesis. We used a novel modification of theex ovochick chorioallantoic membrane (CAM) model that combined confocal and automated analyses to quantify tumor angiogenesis induced by glioblastoma tumor onplants. This model is advantageous due to its low cost and moderate throughput capabilities, while maintaining complexin vivocellular interactions that are difficult to replicatein vitro. After screening multiple combinations, we determined that glioblastoma-induced angiogenesis was significantly reduced using a combination of bevacizumab (Avastin®) and temsirolimus (Torisel®) at doses below those where neither monotherapy demonstrated activity. These preliminary results were verified extensively, with this combination therapy effective even at concentrations further reduced 10-fold with a CI value of 2.42E-5, demonstrating high levels of synergy. Thus, combining bevacizumab and temsirolimus has great potential to increase the efficacy of angiostatic therapy and lower required dosing for improved clinical success and reduced side effects in glioblastoma patients.